» Articles » PMID: 37958632

Cathelicidin Antimicrobial Peptide Acts As a Tumor Suppressor in Hepatocellular Carcinoma

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Nov 14
PMID 37958632
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is associated with high rates of metastasis and recurrence, and is one of the most common causes of cancer-associated death worldwide. This study examined the protein changes within circulating exosomes in patients with HCC against those in healthy people using isobaric tags for a relative or absolute quantitation (iTRAQ)-based quantitative proteomics analysis. The protein levels of von Willebrand factor (VWF), cathelicidin antimicrobial peptide (CAMP), and proteasome subunit beta type-2 (PSMB2) were altered in HCC. The increased levels of VWF and PSMB2 but decreased CAMP levels in the serum of patients with HCC were validated by enzyme-linked immunosorbent assays. The level of CAMP (the only cathelicidin found in humans) also decreased in the circulating exosomes and buffy coat of the HCC patients. The serum with reduced levels of CAMP protein in the HCC patients increased the cell proliferation of Huh-7 cells; this effect was reduced following the addition of CAMP protein. The depletion of CAMP proteins in the serum of healthy people enhances the cell proliferation of Huh-7 cells. In addition, supplementation with synthetic CAMP reduces cell proliferation in a dose-dependent manner and significantly delays G1-S transition in Huh-7 cells. This implies that CAMP may act as a tumor suppressor in HCC.

Citing Articles

Glioblastoma Multiforme: Sensitivity to Antimicrobial Peptides LL-37 and PG-1, and Their Combination with Chemotherapy for Predicting the Overall Survival of Patients.

Chernov A, Skliar S, Kim A, Tsapieva A, Pyurveev S, Filatenkova T Pharmaceutics. 2024; 16(9).

PMID: 39339270 PMC: 11435188. DOI: 10.3390/pharmaceutics16091234.


Role of extracellular vesicle-associated proteins in the progression, diagnosis, and treatment of hepatocellular carcinoma.

Liu Y, Jiang S, Zhang J, Zheng H, Zhang L, Zhao H Cell Biosci. 2024; 14(1):113.

PMID: 39227992 PMC: 11373138. DOI: 10.1186/s13578-024-01294-6.

References
1.
Piktel E, Niemirowicz K, Wnorowska U, Watek M, Wollny T, Gluszek K . The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz). 2015; 64(1):33-46. PMC: 4713713. DOI: 10.1007/s00005-015-0359-5. View

2.
Wang W, Zheng Y, Jia J, Li C, Duan Q, Li R . Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. Exp Ther Med. 2017; 14(1):499-506. PMC: 5488501. DOI: 10.3892/etm.2017.4546. View

3.
Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X . CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020; 5(1):298. PMC: 7762756. DOI: 10.1038/s41392-020-00375-5. View

4.
Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View

5.
Li S, Chen L . Exosomes in Pathogenesis, Diagnosis, and Treatment of Hepatocellular Carcinoma. Front Oncol. 2022; 12:793432. PMC: 8828506. DOI: 10.3389/fonc.2022.793432. View